WP1: Evidence Workflow Development
WP2: Outcome Driven Healthcare
WP3: Personalised Medicine
WP4: Technical Implementation
WP Leads: Daniel Prieto-Alhambra (University of Oxford) & Alex Asiimwe (Bayer)
WP Leads: Dalia Dawoud (NICE) & Eline Vanoverbeeke (Pfizer)
WP Leads: Peter Rijnbeek (Erasmus Medical Centre) & Mark Kruger (Sanofi)
Development of use cases to explore topic-specific aspects of governance and quality assessment, provide input for collaboration framework and formulate requirements for the development of analytical tools and interactive dashboards to share study results.
WP2 will enable the transition towards outcomes-driven healthcare systems in Europe. This can only be achieved if the EHDEN framework can be used in the context of regulatory approval, health technology assessment (HTA), and for payer purposes. As the EHDEN project is using the OMOP-CDM to build a federated network of data sources standardised to a common data model, WP2 will test whether the OMOP-CDM can be used for said regulatory, HTA and payer activities.
WP3 aims to develop a standardized process to enable personalized decision-making. This includes well-calibrated patient-centredpredictive models and risk-effect estimation methods that can be utilized for multiple outcomes of interest to patients and can be applied to observational healthcare data from any patient subpopulation of interest available in the OMOP-CDM.